Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis

<div>Identification of immune status. (a) Heatmap of tumor-related infiltrating immune cells based on TIMER, CIBERSORT, CIBERSORT-ABS, QUANTISEQ, MCPcounter, XCELL, and EPIC algorithms in the CS1 and CS2 subgroups. (b) Different normalized enrichment scores of immune cells between the subgroups. (c) Heatmap of different immune-related pathway enrichment scores between the subgroups. (d) Difference in TMB between the CS1 and CS2 subgroups. (e) Difference in response of immune check point inhibitor treatment based on the TIDE algorithm.</div>

Oxidative Medicine and Cellular Longevity

fig6

Figure 6

Figure 6: Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis 

Figure 6 | Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis 